Alkermes PLC (ALKS) Holdings Boosted by Fmr LLC

Fmr LLC grew its position in Alkermes PLC (NASDAQ:ALKS) by 0.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,978,575 shares of the company’s stock after purchasing an additional 96,457 shares during the quarter. Fmr LLC owned approximately 14.95% of Alkermes PLC worth $1,332,068,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of ALKS. BlackRock Inc. boosted its position in shares of Alkermes PLC by 5,927.5% in the first quarter. BlackRock Inc. now owns 10,292,601 shares of the company’s stock worth $602,115,000 after purchasing an additional 10,121,839 shares during the period. Primecap Management Co. CA boosted its position in shares of Alkermes PLC by 23.2% in the first quarter. Primecap Management Co. CA now owns 7,856,543 shares of the company’s stock worth $459,608,000 after purchasing an additional 1,480,273 shares during the period. Janus Capital Management LLC boosted its position in shares of Alkermes PLC by 220.0% in the first quarter. Janus Capital Management LLC now owns 1,658,928 shares of the company’s stock worth $97,045,000 after purchasing an additional 1,140,555 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Alkermes PLC by 40.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,857,077 shares of the company’s stock worth $167,138,000 after purchasing an additional 820,355 shares during the period. Finally, Fiera Capital Corp bought a new position in shares of Alkermes PLC in the second quarter worth approximately $37,717,000. Institutional investors and hedge funds own 99.07% of the company’s stock.

Alkermes PLC (NASDAQ:ALKS) traded down 0.30% during trading on Friday, reaching $50.19. 29,011 shares of the company’s stock traded hands. Alkermes PLC has a one year low of $41.93 and a one year high of $63.40. The firm’s market capitalization is $7.71 billion. The company has a 50-day moving average price of $51.49 and a 200 day moving average price of $56.44.

Alkermes PLC (NASDAQ:ALKS) last announced its earnings results on Thursday, July 27th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The company had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $216.54 million. During the same quarter in the previous year, the company posted ($0.01) EPS. The firm’s quarterly revenue was up 12.1% on a year-over-year basis. On average, analysts anticipate that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.

A number of research firms have weighed in on ALKS. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Leerink Swann lowered shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $68.00 to $61.00 in a research report on Tuesday, June 13th. Credit Suisse Group reiterated a “buy” rating and issued a $70.00 price target on shares of Alkermes PLC in a research report on Wednesday, June 7th. J P Morgan Chase & Co set a $78.00 price target on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Saturday, July 1st. Finally, Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $62.89.

In other news, CAO Kathryn L. Biberstein sold 13,566 shares of the business’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $51.29, for a total transaction of $695,800.14. Following the transaction, the chief accounting officer now owns 70,455 shares of the company’s stock, valued at approximately $3,613,636.95. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Paul J. Mitchell sold 1,500 shares of the business’s stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $58.11, for a total transaction of $87,165.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $552,045. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,066 shares of company stock worth $941,485. 5.34% of the stock is currently owned by corporate insiders.

WARNING: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://ledgergazette.com/2017/09/22/alkermes-plc-alks-holdings-boosted-by-fmr-llc.html.

About Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).

Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)

Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply